Ulcerative Colitis

"We remain encouraged that maribavir and/or the company's stellar business development track record will be successful long term, and progress with either effort could sway our investment thesis, given what we see as a $9 to $10 absolute floor on the valuation from Vancocin and current cash alone."Maribavir is an experimental antiviral drug acquired from GlaxoSmithKline (nyse: GSK - news - people ) in 2003.

ViroPharma previously said it expects to release preliminary results of a Phase II study before the end of the month.ViroPharma acquired the U.S.

rights to Vancocin from Eli Lilly (nyse: LLY - news - people ) in December 2004.

Earlier this month, AstraZeneca (nyse: AZN - news - people ) said it acquired the rights to Vancocin for the India and Nepal markets for an undisclosed sum.

More On This Topic Companies: VPHM AZN -% String xsl=(String) application.getAttribute(com.forbes.cms.Constants.XSL_REP_KEY)+"/story_body_html_trans.xsl"; final TransformerFactory tFactory = TransformerFactory.newInstance(); final Transformer transform...

FOSRENOL® should not be taken by patients who are nursing or pregnant.

FOSRENOL® should not be taken by patients who are under 18 years of age.

For Full Prescribing Information, please visit www.fosrenol.com.

### Printer Friendly Version Forward to a Friend Get Instant Access to our News Archive For more than 20 years, executives like you have relied on Engel Publishing Partners for the business, marketing, and clinical research information needed to make informed business decisions.

InfoPass gives you access to an array of integrated information services – information that is critical to your success and the success of your organization.

Login or activate your InfoPass Account now!

search by news archive Med Ad News R&D Directions entire archive Subscriber registration Purchase a subscription Forget your password Need help?

Your account details Order back issues Renew subscription Free trial issues about us copyright © 2006 Engel Publishing Partners ...

The FDA has yet to respond to the petition.

Analysts figure that Colazal will account for 60 percent of Salix' sales for 2006.

Shares of Salix fell 91 cents, or 6 percent, to $14.17 on the Nasdaq at nearly four times their average volume.

Shares have traded between $13.94 and $22.79 over the past 52 weeks.

Buy-side analysts covering Salix maintained their ratings on the opinion that the clinical trial waivers for Vancocin would not likely work with Colazal because of differences on how the drug is absorbed by the body.

Copyright 2005, by The Associated Press.

All rights reserved.

This material may not be published, broadcast, rewritten or redistributed.

BW MALL SPONSORED LINKS Get a Palm® Treo™ 650 smartphone + 25 free trades. Open an account at Ameritrade and use the latest trading tools, data, and technology to stay on top of breaking market trends.

It’s all at Ameritrade.com.

Sign up today.

Protect Your Secrets from Leaking to Internet A technology breakthrough allows inspecting all outgoing data for confidential content and blocking unauthorized transmissions in real time.

Free trial of GTB Inspector appliance is available in March 2006 only.

Costa Rica Real Estate Prices Are Exploding Invest in prime beach, river a...